Find Clinical Trials

Inclusion Criteria: * Outpatients 18 to 70 years of age. * Meet DSM-V criteria for MDD as determined by the SCID-5 or other standardized clinical interviews. * In the current or most recent MDE, participant must be responding or responded to a treatment or a combination of treatments for MDD. Patients with remitted MDD who are currently not taking medications will also be accepted. Patients must have achieved remission at or later than May 1, 2023. * Participants must have a MADRS total score ≤14. * Participant must be willing and able to complete self-reported assessments including sufficient fluency in English. * Participant must be willing to wear the wrist-worn actigraphic device for the duration of the study. Exclusion Criteria: * Bipolar I or Bipolar-II diagnosis (lifetime), schizophrenia, or schizoaffective disorder. * Elevated risk of suicide, as determined by clinical evaluation. * Existence of major neurological disorders, head injury (if accompanied by any of \[A\] loss of consciousness longer than 24 hours, \[B\] documented evidence of Glasgow Coma Scale \<9 at the time of injury, \[C\] post-traumatic amnesia lasting longer than 24 hours) (43), or other unstable medical conditions. * The participant presents with any condition which, according to the researcher's judgment, could interfere with the assessments stipulated in the protocol. * The participant is employed by the researcher, actively involved in the current study or other research overseen by the same researcher, or is a relative of a study employee or the researcher.

Inclusion Criteria: * Neuro-oncological pathology: supratentorial and subtentorial tumors, intra and extra axial tumors excluding the skull base (anterior, middle and posterior fossa; sellar and parasellar region) * Basicranial pathology: tumors originating from the anterior cranial fossa, middle cranial fossa and posterior cranial fossa, sellar region with or without supratentorial/parasellar development. * Vascular pathology: aneurysms, AVMs, cavernomas, other pathologies (Moyamoya disease, dural fistulas, nontraumatic hematomas) * Traumatic pathology: diffuse damage (nonvisible diffuse damage, diffuse damage, diffuse damage with edema, diffuse damage with shift) and focal damage (acute/subacute/chronic subdural hematoma, extradural hematoma, subarachnoid hemorrhage, intraparenchymal hematoma, fractures); hydrocephalus. The inclusion criterion for chronic subdural hematoma is recent bleeding for TBI with CT finding of chronic subdural hematoma candidate for evacuation surgery. * Spinal pathology: degenerative cervical (anterior/posterior), myelopathic, and trauma pathology; instrumented, uninstrumented thoracolumbar pathology (disc pathology, canal pathology), and trauma pathology; oncologic spinal pathology. * Functional pathology: Parkinson's disease, spasticity, trigeminal neuralgia, craniofacial pain/algia, neuropathic pain, tremor, dystonias, obsessive compulsive disorder, drug-resistant epilepsies, depression. Normotensive hydrocephalus. * Peripheral nervous system pathology: peripheral nerve compression syndromes, peripheral nerve and plexus tumors, brachial plexus and peripheral nerve trauma (contusion and section) * Malformative pathology: Chiari malformation type 1 and craniostenoses including both those framed in malformative syndromes and those not framed in malformative syndromes (monosutural craniostenoses: trigonocephaly, plagiocephaly, scaphocephaly; multisutural craniostenoses). Malformative hydrocephalus. * For cognitive and psychological assessment: age 18 years or older; adequate understanding of Italian language; diagnosis of glioma, meningioma, vascular pathology, spinal pathology Exclusion Criteria: * For cognitive and psychological assessment: patients with psychiatric diseases in history and/or taking psychotropic drugs; presence of overt cognitive decline (not due to the injury) in history; patients younger than 18 years old.

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative. * Assent, when appropriate, will be obtained per institutional guidelines * Agreement to allow the use of archival tissue from diagnostic tumor biopsies * If unavailable, exceptions may be granted with study principal investigator (PI) approval * Willingness to comply with all study interventions including the use of medical cannabis and follow-up assessments * Age: ≥ 18 years * Eastern Cooperative Oncology Group Performance Status Scale (ECOG) score ≤ 2 * Ability to read and understand English for questionnaires * Patients must have either neuropathy ≥ 1 according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 scale or a neuropathy score of \> 3 on a 0-10 scale plus a FACT/GOG-Ntx score of \> 10 * The patient's previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) or platinum (cisplatin, oxaliplatin, or carboplatin) and considered the primary cause of the neuropathy by the medical team * Total bilirubin ≤ 1.5 X upper limits of normal (ULN) (unless has Gilbert's disease) (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated) * Aspartate aminotransferase (AST) ≤ 3 x ULN (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated) * Alanine aminotransferase (ALT) ≤ 3 x ULN (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated) * Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated) * Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 months after the last dose of protocol therapy. * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only) Exclusion Criteria: * Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period. Note: Hormonal therapy is allowed * Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy within the past 6 months * Concurrent use of other alternative medicines such as medical cannabis, herbal agents and high dose vitamins and minerals * Liver cirrhosis Child-Pugh B or C * Mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry. (These patients may not be able to cooperate with this slightly invasive procedure or with the data collection process.) * History of diabetic neuropathy, neuropathy related to HIV, or other medical causes of chronic neuropathy in the baseline assessment including past medical history, any history of diabetes, alcoholism, and vitamin B deficiency * Previous medical cannabis use for any indication within 30 days of enrollment * Planned or actual changes in type of medications that could affect symptoms related to CIPN. New medications for the treatment of CIPN are not allowed during the study. * Subjects need to be on stable doses of CIPN medications for 4 weeks * Strong inhibitors or inducers of CYP3A4 * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent * Clinically significant uncontrolled illness * Diagnosis of Gilbert's disease * Females only: Pregnant or breastfeeding * Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics) * Patients who have an allergy or an aversion to strawberry or strawberry flavoring

Inclusion Criteria: * All patients diagnosed with colon cancer in Region Västmanland, will be considered for inclusion. Those who meet the inclusion criteria will be offered to participate in the studies after written approval. Exclusion Criteria: * language difficulties that cause patients to be unable to absorb the treatment * ongoing alcohol or substance use syndrome * elevated suicide risk * ongoing psychotic disorder, severe depression * antidepressant treatment initiated within the last month * ongoing or previous manic episode * cognitive illness/dementia * ongoing psychological treatment.

Inclusion Criteria: * Adult patient * Oral consent after free and informed information * Hospitalized in the multipurpose intensive care unit of Rangueil hospital with an estimated length of stay greater than 24 hours * Conscious (Glasgow Coma Scale \> 8) and Richmond Agitation-Sedation Scale (RASS) sedation score between -1 and +1 * Mechanically ventilated or not * Person affiliated to or beneficiary of a social security system. Exclusion Criteria: * Patient under legal protection (guardianship or curatorship) * RASS \< -1 or \> +1 * Visual or hearing difficulties preventing the use of the VR headset * Severe psychiatric history (severe depression, psychosis, bipolarity), advanced dementia or mental retardation * Hemodynamic (Norepinephrine support \> 0.5 gamma/kg/min) and/or respiratory instability (invasive mechanical ventilation with FiO2 greater than 80%) * Presence of a malformation or cervical or facial trauma that does not allow the application of the VR headset * Pregnancy or breastfeeding

Inclusion Criteria: * Have Type 2 diabetes treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to screening. * Have a body weight ≥50 kilograms (kg) and Body Mass Index (BMI) of \>85th percentile Exclusion Criteria: * Have Type 1 diabetes * Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or dulaglutide within 8 weeks prior to screening * After the Type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome * Have had ≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemic unawareness within the last 6 months * Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) * Have prior chronic, recurrent, or idiopathic pancreatitis, or known gallbladder disease * Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 8 weeks prior to screening

Inclusion Criteria: Age ≥18 years at the time of inclusion; * Patient signed and dated written informed consent form (ICF) in accordance with ICH GCP and local legislation prior to inclusion in the study for the prospective observational cohort; * Established diagnosis of hypertension, diagnosed in accordance with current clinical guidelines for hypertension, i.e. in adults, i.e. systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg. when measured at two different visits * Laboratory markers of CKD (eGFR \<60 mL/min/1.73 m2 and/or albuminuria/proteinuria\*) measured during the period ≤12 months prior to inclusion in the study and persisting ≥3 months between two measurements without a recorded diagnosis of CKD in the primary medical record prior to inclusion; \* any of the following: urine albumin/creatinine ratio (UACR) ≥30 mg/g (3 mg/mmol), Urine protein-creatinine ratio (uPCR) ≥150 mg/g (15 mg/mmol), albuminuria ≥30 mg/d or Urine protein-creatinine ratio (uPCR) ≥0.15 mg/d. * Absence of documented diagnosis of CKD in the patient's medical records prior to inclusion in the study Exclusion Criteria: * Absence of a signed ICF in patients in the prospective follow-up group * Participation in any randomized controlled trial within 3 months prior to inclusion in this study or during participation in this study * An established diagnosis of type 1 or type 2 diabetes mellitus. * Diagnosis of symptomatic chronic heart failure (CHF), NYHA functional class III-IV, documented in the patient's medical records * Diagnosis of AH of secondary genesis

Inclusion Criteria: * Presence of an MS diagnosis confirmed by a neurologist based on the McDonald criteria. * Having the RRMS subtype. * Diagnosed with MS for at least one year. * Individuals aged 18-65 years. * An EDSS score between 0 and 5, indicating mild to moderate disability. * No use of steroid therapy or discontinuation of steroid therapy at least 3 months prior to participation. * No MS relapse within the last 3 months. * No prior use of acupressure or other complementary therapies. * Sufficient language proficiency to understand the study and complete assessments. Exclusion Criteria: * Presence of any open wounds or deformities at the application site. * Presence of neurodegenerative or neuropsychiatric disorders such as - Parkinson's or Alzheimer's, which may potentially confound the study results. * Pregnant or breastfeeding women, due to hormonal changes that may affect outcomes. * Presence of severe cardiovascular, pulmonary, hepatic, renal, or psychiatric diseases.

Inclusion Criteria: 1. Voluntarily signing an informed consent to participate in the study. 2. Age between 18 and 80 years. 3. Diagnosis of hypertension according to the Polish Society of Hypertension criteria from 2019, either already treated or newly diagnosed. 4. Blood pressure exceeding 140/90 mmHg in office measurements (during the screening visit). Exclusion Criteria: 1. Suspicion or diagnosis of secondary hypertension. 2. Pregnant women, breastfeeding women, or those planning pregnancy during the study period.

Inclusion Criteria: * Adults (aged 18+) who are capable of giving informed consent * Patients meeting diagnostic criteria for major depressive disorder (MDD) without psychotic symptoms according to the DSM-5 * Currently experiencing a major depressive episode (MDE) * Montgomery-Asperg Depression Rating Scale (MADRS) score greater than 20 at screening * Patients meeting criteria for treatment-resistant depression (TRD): failure of 2 or more adequate trials of antidepressant therapy of adequate dose and duration during the current episode * Enrollment in one of the treatment modalities (rTMS, IVK, or ECT) at the Interventional Psychiatry Program at St. Michael's Hospital, Unity Health Toronto * Ownership of a smartphone (for participants using wearable devices) Exclusion Criteria: * Individuals without Internet access (required to access study platforms) * Medication changes, aside from the treatment received through the IPP, one month (28 days) before screening, or during the entire duration of treatment (variable based on treatment arm) * Participants who do not speak English fluently enough to successfully communicate study information, answer questions accurately, and/or obtain informed consent

Inclusion Criteria: * Diagnosed with coronary artery disease (confirmed through clinical, imaging, or procedural evidence). * Receiving care at designated hospitals in Baghdad. * Able to understand and complete the PHQ-9 questionnaire independently or with minimal assistance. * Consents to participate in the study. Exclusion Criteria: * Patients with a history of severe psychiatric disorders unrelated to depression (e.g., schizophrenia, bipolar disorder). * Patients with cognitive impairments or neurological conditions affecting their ability to complete the questionnaire. * Those currently hospitalized for acute cardiac events (e.g., myocardial infarction) requiring intensive care. * Individuals unwilling to provide informed consent.

Inclusion Criteria: * be aged 18 or over, * have type 1 or type 2 diabetes or diabetes secondary to pancreatic disease, * have been treated with multi-injection basal/bolus insulin therapy for at least 6 months, * using a compatible rapid insulin with the device Ekiyou such as : Novorapid, Humalog, Apidra, Asparte Sanofi, Fiasp or Lyumjev, * using a compatible long-acting insulin with the device EkiYou such as : Lantus, Abasaglar, Toujeo, Levemir or Tresiba, * have been using a continuous glucose monitoring device such as Dexcom G6, Dexcom One, Dexcom One+ or FreeStyle Libre for at least 3 months, * have given their physician access to their glucose data via a glucose data management platform, * for type 2 diabetic patients using an hypoglycemia-inducing agent other than insulin (including hypoglycemic sulfonamides and SGLT-2 inhibitors), have no change in dosage regimen for at least 3 months * have recorded at least 70% of CGM data over a 14-day window close to the inclusion date, * have at least one smartphone running Android 5.0 or higher or iOS 12.0 or higher connected to the internet and able to receive CGM data available to them on the day of the inclusion, * able to read or use a smartphone with no visual impairment needing specific typography, * for patients of childbearing potential, a pregnancy test must have been carried out prior to inclusion, or an effective and adequate method of contraception must be used, * be affiliated to a French social security scheme. Exclusion Criteria: * pregnant or breast-feeding women, * type 1 diabetic patients treated with any hypoglycemia-inducing agent other than insulin (including hypoglycemic sulfonamides and SGLT-2 inhibitors), * insulin-resistant patient: prescribed daily insulin dose \> 1 U/kg/day or \> 200 U/day, * patient with very low insulin requirements: daily insulin dose \< 15 U/day, * patient with gastroparesis, * diabetic ketoacidosis or severe level 3 hypoglycemia requiring third-party intervention within the 6 months prior to inclusion, * pancreatic disease secondary to chronic ethanolism, * known medical condition that, in the investigator's opinion, may interfere with the protocol, * patient who cannot be monitored for 3 months, * intellectual ability compromising use of the application, comprehension or completion of questionnaires, * participation in another clinical trial or administration of a non-authorised drug in the 4 weeks preceding the screening, * person taking part in another research study with an exclusion period still in progress, * under guardianship or curatorship, * imprisoned or otherwise deprived of liberty.

Inclusion Criteria: * Schizophrenia: (1) Age 18-65 years, no gender restriction, Han ethnicity; (2) Diagnosis confirmed using the MINI-International Neuropsychiatric Interview (MINI) tool, meeting the DSM-5 criteria for schizophrenia; (3) Baseline Positive and Negative Syndrome Scale (PANSS) score ≥ 60; (4) Education level of middle school or higher, no language barriers, able to cooperate with assessment and treatment, and informed consent obtained from the patient or guardian. * Depressive Disorder: (1) Age 18-65 years, no gender restriction, Han ethnicity; (2) Diagnosis confirmed using the MINI tool, meeting the DSM-5 criteria for depressive disorder; (3) Baseline Hamilton Depression Rating Scale (HAMD-17) score ≥ 17; (4) Education level of middle school or higher, no language barriers, able to cooperate with assessment and treatment, and informed consent obtained from the patient or guardian. * Bipolar Disorder: (1) Age 18-65 years, no gender restriction, Han ethnicity; (2) Diagnosis confirmed using the MINI tool, meeting the DSM-5 criteria for manic or hypomanic episodes in bipolar disorder; (3) Baseline Young Mania Rating Scale (YMRS) score ≥ 13; (4) Education level of middle school or higher, no language barriers, able to cooperate with assessment and treatment, and informed consent obtained from the patient or guardian. Exclusion Criteria: * Patients with a history of or currently meeting the DSM-5 criteria for the following diagnoses: organic mental disorders, schizoaffective disorder, intellectual disability, dementia, other cognitive disorders, alcohol or drug dependence, and Axis II disorders including personality disorders; * Patients with severe suicidal tendencies (as assessed by the MINI Chinese version suicide module with a moderate risk or higher), or those at risk of harming others; * Patients with severe or unstable physical illnesses; * Narrow-angle glaucoma; * A history of epilepsy or seizures; * Known pregnancy and/or breastfeeding, or those planning to become pregnant; * Participation in another clinical trial, or unwilling or unable to complete the full course of this trial; * Participants deemed unsuitable by the investigator.

Inclusion Criteria: * age\>18 years\<60 years Diabetic type 2 Patients with Diabetic foot ulceration Diabetic nephropathy CKD patients not on dialysis Exclusion Criteria: * • Patients with recent infectious disease, immunological disorders, taking diuretics and magnesium containing antacids * malabsorption syndrome, chronic diarrhea * CKD Stage V on dialysis, pancreatitis, alcoholism, liver diseases * tuberculosis, thyrotoxicosis, any malignancy.

Inclusion Criteria: * Must be ≥19 of age at the time of signing the informed consent form * Capable of giving signed informed consent. * Having CRSwNP based on clinical symptoms and/or radiographic or endoscopic evidence of inflammation in their upper airways (Diagnosis consistent with EPOS 2020)(2)and severe asthma: * SA based on GINA criteria (37) and confirmed with spirometry and assessmenton the previous history of asthma (a pre-post bronchodilator spirometry ormethacholine challenge to document the positive or negative history of asthmawill be performed if there is no clinical record). * Nasal polyp score (NPS) of at least 2 on each side * Females of childbearing potential must commit using an acceptable method of birthcontrol for the duration of the study and they must have a negative urine pregnancy test ateach study visit * Not expecting to have surgery within the next 7 months Exclusion Criteria: * Have previously undergone sinus surgery or nasal polypectomy * A history of organ transplantation such as lung transplantation * Previously or currently using immunomodulator medications or antihistamines * A history of auto-immune diseases * Current or past sinonasal or bronchial tumors * Currently using systemic or oral corticosteroids * Women who are pregnant, plan to become pregnant, or breastfeed during the trial * Current participation in any other interventional treatment trials * Compliance: is unlikely to comply with study visits based on investigator judgment: * Diagnosed or suspected malignant or premalignant nasal disease (e.g. SchniderianPapilloma, unilateral nasal polyposis) * Fungal rhinosinusitis (CT/Histology), positive Aspergillus skin prick testing and/orpositive Aspergillus IgE RAST (Radioallergosorbent) testing * Malignant neoplasm within 5 years (from screening) excluding basal cell or squamouscell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterinecervix treated locally and without metastatic disease for 3 years. * Active bleeding disorders, and/or inability to support interruption to anticoagulant or anti-platelet therapies for nasal biopsy. * Severe nasal deformity precluding endoscopic assessment/biopsy of postnasal space * Have an acute or chronic infection (excluding that related to CRS) requiring managementas follows: * Currently on any treatment for a chronic infection such as pneumocystis,cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria * Hospitalisation solely for the treatment of proven infection requiring parenteral (IV orIM) antibiotics (antibacterial, antiviral, antifungal, or anti-parasitic agents) within 60days of Day 1 * Proven severe infection requiring outpatient treatment with parenteral (IV or IM)antibiotics (antibacterial, antiviral, antifungal, or anti-parasitic agents) within 60 daysof Day 1. Prophylactic anti-infective treatment is allowed. * Known positive human immunodeficiency virus (HIV) status * Known positive Hepatitis B (HB) or Hepatitis C status * Have clinical evidence of significant unstable or uncontrolled acute or chronic diseaseswhich, in the opinion of the principal investigator, could confound the results of the study orput the participant at undue risk * Have a planned surgical procedure, laboratory abnormality, or condition that, in theopinion of the principal investigator, makes the participant unsuitable for the study. * Have received any investigational agent (that is not approved for sale in Canada) within60 days of Day 1 * Smoking history; current or former smokers with a smoke history of packs year \>15 * Subjects with parasitic (helminthic) infection * Subjects with hypersensitivity; with allergy/intolerance to a monoclonal antibody or biologics * Subjects allergic to Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs)

Inclusion Criteria: * Male or female outpatients aged 12 years or older at the time of signing the informed consent/assent form. * Patients who have been prescribed but not yet initiated treatment with tezepelumab according to the label and local market reimbursement criteria. * Diagnosis of asthma for at least 52 weeks prior to enrolment date and symptoms confirmed by the Investigator not to be due to alternative diagnoses. * Receipt of at least one prescription of high-dose Inhaled Corticosteroids (ICS) (according to the Global Initiative for Asthma 2024) during the 52 weeks prior to enrolment date. * Use of additional asthma maintenance controller medication(s) in addition to ICS either as free- or fixed-drug combination for at least 52 weeks prior to enrolment date. * Documented history of at least 1 asthma exacerbation during the 52 weeks prior to enrolment date. * Asthma Control Questionnaire (ACQ-6) score ≥1.5 (indicating inadequate asthma symptom control) at enrolment. * Availability of at least one Blood Eosinophil Count (BEC) measurement (in medical records) in the 52-week period prior to enrolment date. * Availability of participants' medical records for asthma exacerbations and unscheduled Health Care Resource Utilization (HCRU) for the 52 weeks prior to enrolment date. * Patients are able to understand and complete the Patient-Reported Outcome (PROs). * Provision of signed and dated written informed consent/assent (as applicable). Exclusion Criteria: * Any contraindication to tezepelumab as per the approved product label or in the opinion of the Investigator. * Concurrent or recent (\<30 days before the index date) treatment with biologics for asthma, with the exception of stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment). * Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months. * Currently pregnant (or intention to become pregnant) or lactating women.

Inclusion Criteria: * Patients (women or men) with histologically confirmed metastatic breast cancer * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Written informed consent obtained prior to enrollment * Age ≥ 18 years * Blood and tumor tissue sample available for research * Measurable disease * Other site accessible for biopsy, except bone lesions if this is the only accessible site, or biopsy obtained within the previous 6 months * Medical history, blood parameters and clinical conditions do not indicate major dysfunctions of organ To treatment: \- Maintenance of screening inclusion criteria Exclusion Criteria: * Presence of visceral crisis, defined according to ABC3/ESMO guidelines * Patients with local recurrence that can be treated with surgery and/or radiotherapy alone * Patients who have previously received palliative radiotherapy on the only site accessible to biopsy * Patients with metastatic disease limited to bone * Patients with metastatic disease limited to the brain, unless planned a surgical excision, in which case tissue can be collected for screening * Severe hematopoietic, renal and/or hepatic insufficiency * Known contraindication to biopsy * Neoplastic pathology of different histology in the previous 5 years, except carcinoma in situ of cervical basal or squamous cell carcinoma of the skin, if adequately treated

Inclusion criteria: * adolescents 13 to 18 years * emotional difficulties Exclusion criteria: * autism spectrum disorder * mental retardation * severe depressive episode combined with high suicidal risk

Inclusion Criteria: * Ages 25-64 * Right-handedness * Veterans with a history of deployment to Operation Iraqi Freedom (OIF), Operation Enduring Freedom (OEF), Operation New Dawn (OND) or other post 9/11 war on terrorism * History of PTSD and/or depression * Military related mild traumatic brain injury * If taking psychotropic medication, demonstrate stability for 3 months * If taking stimulants, washout period of 12 hours Exclusion Criteria: * History of neurological, cardiovascular, or pulmonary disease * Cardiac arrhythmia (all types) * Active suicidal ideation * Visible wounds on skin of the left ear * Medical implants such as cardiac defibrillators, pacemakers, or deep brain stimulators * Pregnancy * Completed taVNS in the past 4 weeks * Current substance use disorder (exception: mild cannabis use disorder allowed) * Current moderate or severe alcohol use disorder * Major cognitive disorder

Inclusion Criteria: * Signed Informed Consent. * Ability and willingness to comply with the requirements of the study protocol. * Age ≥ 18 years old. * Diagnosis of the following histologies according to the 2016 WHO Classification for Mature Lymphoid Neoplasms81 along with a specific high-risk criteria for CNS relapse if indicated as certain diagnoses in of themselves are high-risk alone: 1. Diffuse Large B-cell Lymphoma (DLBCL) with CNS IPI score ≥ 4. 2. Stage III/IV High Grade B-cell lymphoma (HGBCL) with MYC, BCL2, and/or BCL6 translocations 3. Primary DLBCL of Breast 4. Primary DLBCL of Testis 5. Primary Cutaneous DLBCL, Leg Type 6. Intravascular Large B-cell Lymphoma 7. Stage III/IV HIV-associated DLBCL 8. Double expressor DLBCL (co-expression of MYC ≥ 40% and BCL2 ≥ 50% without translocations) with a CNS IPI score ≥ 3 9. DLBCL with the following extranodal involvement AND CNS IPI score ≥ 3: i. Adrenal ii. Breast iii. Bone Marrow with pathological overt morphological involvement iv. Epidural/Paraspinal v. Nasal/parasinus with local invasion such as bone destruction vi. Renal viii. Uterine ix. Testis xi. Skull involvement without direct invasion into CNS/brain parenchyma * Transformed DLBCL from any indolent B-cell lymphoma is permitted (as long as there is no prior history of CNS involvement). * Planned to receive standard chemoimmunotherapy. * Patient is able to undergo lumbar puncture without any contraindications which include but are not limited to altered mental status, increased intracranial pressure due to any CNS lesion (mass, abscess), overlying skin infection at the site of LP, inability to safely access CSF due to lymphomatous involvement (i.e. epidural mass), or inability to hold antiplatelet or anticoagulation safely for the procedure to be performed. * No systemic therapy prior to study enrollment for an aggressive B-cell lymphoma is permitted. Treatment for a history of indolent lymphoma is permitted. Systemic corticosteroids are permitted (must be ≤7 days and tapered down to prednisone ≤ 20 mg oral/day or steroid equivalent by first day of anthracycline treatment). Clinical exceptions in regards to steroid management can be made after discussion with PI. * ECOG performance status of 0 to 2. Exclusion Criteria: * Active systemic therapy for another malignancy (other than indolent B-cell lymphoma) within 2 years; local/regional therapy with curative intent such as surgical resection or localized radiation within 2 years of treatment is permitted. * Active concurrent malignancy with the exception of basal cell or localized squamous cell skin carcinoma, localized prostate cancer, or other localized carcinomas such as carcinoma in situ of cervix, breast, or bladder. * Any uncontrolled illness that in the opinion of the investigator would preclude administration of curative intent chemoimmunotherapy (e.g. significant active infections, hypertension, angina, arrhythmias, pulmonary disease, or autoimmune dysfunction). * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 2 weeks prior to Cycle 1, Day 1. * Psychiatric illness or social situations that would limit the patient's ability to tolerate and/or comply with study requirements.